Chronic Hand Eczema

The phase 3 clinical trial investigating delgocitinib cream for adolescents with moderate to severe CHE met its primary and key secondary endpoints.

The drug, a JAK inhibitor, met all primary and secondary endpoints in a phase 3 trial for adolescent CHE.

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in chronic hand eczema this year.

Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.

The study found that those who worked with wet hands and had chapped skin had a higher severity of chronic hand eczema.

Treatment with delgocitinib led to a significant decrease in the expression of inflammatory markers that were elevated in severe cases compared with mild cases at baseline.

Learn more about the in-depth topics covered in the November 2024 CHE digital supplement of Dermatology Times.

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

Delgocitinib is indicated for adults with CHE who either do not respond to or cannot use topical corticosteroids.

Clinical trial exit interviews reveal detailed perspectives on disease burden for patients with chronic hand eczema.

Click here to test your knowledge and read more about the treatment landscape of chronic hand eczema.

Egeberg discusses promising new treatments and insights from recent clinical trials, highlighting significant advancements in chronic hand eczema and atopic dermatitis care presented at the EADV 2024.

During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic hand eczema and early career controversies.

This review of the latest dermatologic studies includes discussions on the development of the Hand Eczema Impact Scale, the role of tofacitinib on Th1 and Th2 cytokines, and more.

Christopher Bunick, MD, PhD, addresses common barriers in recognizing and treating chronic hand eczema and its significant impact on quality of life.

Christophe Bourdon, CEO, discusses LEO Pharma's groundbreaking presentations at EADV, delgocitinib's US pending approval, and the company's commitment to addressing chronic hand eczema.

ALPHA compared alitretinoin and phototherapy for speed and efficacy when treating chronic hand eczema.

Germany is now the first country to launch the topical treatment for adults with moderate to severe CHE.

Announcements from both the FDA and the EC were supported by 2 clinical trials that evaluated the safety and efficacy of delgocitinib cream.

The data was presented at the European Society of Contact Dermatitis in Dresden, Germany, this week.

Chronic hand eczema patients with high corticosteroid phobia are less likely to follow prescribed treatments, indicating a need for improved education.

Shawn Kwatra, MD, presented late-breaking data at AAD 2024 on the largest prurigo nodularis and nemolizumab clinical trial, OLYMPIA.

In a recent study, topical ruxolitinib improved clinical outcomes, itch, and patient quality of life.

Ten posters at the Winter Clinical Hawaii and Maui Derm Conferences will showcase investigational data to expand treatment options for patients with atopic dermatitis and chronic hand eczema.